Research Interests
Neuromodulation in epilepsy
Deep brain stimulation in epilepsy
Responsive Neuromodulation
Machine learning/AI in epilepsy
StereoEEG
Drug and device trials for epilepsy
Presurgical epilepsy
Biomarkers in epilepsy
Deep brain stimulation in epilepsy
Responsive Neuromodulation
Machine learning/AI in epilepsy
StereoEEG
Drug and device trials for epilepsy
Presurgical epilepsy
Biomarkers in epilepsy
Selected Grants
A prospective long-term follow-up study to evaluate the use of the Minder device to aid in treatment after actionable event identification in patients diagnosed with epilepsy
Clinical TrialPrincipal Investigator · Awarded by Epiminder America, Inc · 2026 - 2030A prospective study to evaluate the use of the Minder device to aid in developing a treatment plan after inconclusive prolonged EEG in patients with epilepsy
Clinical TrialPrincipal Investigator · Awarded by Epiminder America, Inc · 2026 - 2028The First Spectral Atlas of the Human Thalamus: Physiology-Guided Targeting and Early Biomarker Discovery for Deep Brain Stimulation in Epilepsy
ResearchPrincipal Investigator · Awarded by Medtronic, Inc. · 2026 - 2028Closed-Loop Neurostimulation as a Window into Brain Network Dynamics in Epilepsy
ResearchPrincipal Investigator · Awarded by North Carolina Neurological Society · 2026 - 2028Developing a Neuromodulation System to Improve Sleep Quality in Epilepsy with a Vision for Broader Neuropsychiatric Applications
ResearchPrincipal Investigator · Awarded by North Carolina Biotechnology Center · 2025 - 2027Fellowships, Gifts & Other Supported Research
393000293 NEURONA THERAPEUTICS NTE001 NRTX-1001 ·
November 2025
Investigator ·
Awarded by: Neurona
393001465 NEURONA THERAPEUTICS NTE002 PARENT A STUDY OF INHIBITORY INTERNEURONS (NRTX-1001) FOR THE TREATMENT OF DRUG-RESISTANT BILATER ·
2025
Awarded by: Neurona
YKP509C003 A Randomized, double blind placebo-controlled study to investigate Carisbamate in Lennox Gastaut Syndrome ·
2024
Awarded by: SK Life Sciences
TrustTSC 3001 Open label A Phase 3, Double-blind, Randomized, Placebo-controlled Trial of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults with Tuberous Sclerosis Complex (TSC)-related Epilepsy ·
2024
Awarded by: Marinus
External Relationships
- Adraxe
- Blackrock Microsystems
- Medtronic
- NeuroPace
- Xenon pharmaceutical
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.